Nanobodies are small antibody fragments comprising the variable domains of the heavy-chain of conventional antibodies. Their small size allows for increased solubility, stability, and easy engineering. This makes them an attractive antibody format for various applications, including diagnostics, therapeutics and research tools.
At the MHRA, we have identified a diverse panel of nanobodies that are available for commercial licensing.
Nanobodies
Influenza A - Group 1: H1 and H1 + others (H5, H2, H9)
Influenza A - Group 2: H3 and H7
Influenza B (Victoria and Yamagata lineages)
SARS-CoV
For enquiries visit: Non-Exclusive Licensing Enquiry Form for Nanobodies